This site is intended for health professionals only

Sanofi-Aventis buys BiPar Sciences


A radical new cancer drug is behind the $500 million (£335 million) purchase of California-based BiPar Sciences by Paris-based Sanofi-Aventis.

Known as BSI-201, the BiPara treatment is a PARP (poly ADP-ribose polymerase) inhibitor that targets molecular processes critical for the growth and proliferation of cancer cells.

It is currently being evaluated in phase 2 clinical trials in triple negative breast cancer, ovarian cancer and other solid-tumour cancers.

The Sanofi deal is the latest in a string of worldwide acquisitions by the company, including generic-drug-maker Medley, Brazil’s third-largest pharmaceutical company, and Laboratorios Kendrick, a Mexican generic drug maker.

The driver behind those two deals is a major US boost in the sale of generic drugs, which cost 30% to 80% less than the original brand-names, according to the Generic Pharmaceutical Association.

As the global recession has deepened, the number of prescriptions for generic drugs has jumped by 8%, now accounting for 68% of all prescriptions in the US.

Copyright Press Association 2009


Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine